Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/133363
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Effects of postnatal omega-3 fatty acid supplementation on offspring pro-resolving mediators of inflammation at 6 months and 5 years of age: a double blind, randomized controlled clinical trial |
Author: | See, V.H.L. Mas, E. Prescott, S.L. Beilin, L.J. Burrows, S. Barden, A.E. Huang, R.C. Mori, T.A. |
Citation: | Prostaglandins, Leukotrienes and Essential Fatty Acids, 2017; 126:126-132 |
Publisher: | Elsevier |
Issue Date: | 2017 |
ISSN: | 0952-3278 1532-2823 |
Statement of Responsibility: | V.H.L.See, E.Mas, S.L.Prescott, L.J.Beilin, S.Burrows, A.E.Barden, R.C.Huangc1T.A.Mori |
Abstract: | Resolution of inflammation is an active process involving specialised pro-resolving mediators (SPMs) generated from the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Omega-3 fatty acid supplementation during infancy may provide an intervention strategy to modify SPMs and reduce oxidative stress. This study evaluates the effect of omega-3 fatty acid supplementation in infancy on SPMs and F2-isoprostanes from 6 months to 5 years of age.In a double-blind, placebo-controlled, parallel-group study design, 420 infants were randomized to a daily supplement of omega-3 fatty acids (280mg DHA and 110mg EPA) or olive oil (control), from birth to age 6 months. Blood was collected at birth (cord blood), 6 months, 12 months and 5 years. Plasma SPMs included 18-HEPE, E-series resolvins, 17-HDHA, D-series resolvins, 14-HDHA, 10S,17S-DiHDoHE, MaR1 and PD1. F2-isoprostanes were measured in plasma and urine, as markers of oxidative stress in vivo.The change in the concentration of 18-HEPE from birth to 6 months was greater in the omega-3 fatty acid group (Ptimepoint*group=0.04) with levels at 6 months significantly higher than controls (P=0.02). Other SPMs were not different between the groups at any time point. Plasma 18-HEPE concentration were associated with erythrocyte EPA concentrations after age and group adjustments (P<0.001), but not with allergic outcomes at 12 months. There were no between-group differences in plasma and urinary F2-isoprostanes at any time point.Omega-3 fatty acid supplementation from birth to 6 months of age increased SPM at 6 months but the effects were not sustained after supplementation ceased. Given that 18-HEPE is a biologically active metabolite, future studies should examine how the increase in 18-HEPE relates to potential health benefits of omega-3 fatty acid supplementation in infancy. |
Keywords: | Fatty Acids, Omega-3 |
Rights: | © 2017 Elsevier Ltd. All rights reserved. |
DOI: | 10.1016/j.plefa.2017.08.008 |
Grant ID: | http://purl.org/au-research/grants/nhmrc/1010495 |
Published version: | http://dx.doi.org/10.1016/j.plefa.2017.08.008 |
Appears in Collections: | Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.